The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data

Expert Opin Investig Drugs. 2009 May;18(5):675-86. doi: 10.1517/13543780902905855.

Abstract

There is an increasing interest in studying the role of GABAergic medications in the treatment of alcohol dependence. The GABAergic drug gamma-hydroxybutyric acid (GHB) has been investigated in Europe as a possible treatment for alcohol dependence. In some European Countries, GHB has been approved as a treatment for alcohol dependence. However, this drug has also shown addictive properties, therefore raising questions about its safety in treating alcohol-dependent subjects. More recent research is focusing on the possibility of identifying alcohol-dependent subtypes without risk of developing GHB abuse. Finally, GHB and naltrexone combined together represent a possible approach deserving future investigations.

Publication types

  • Review

MeSH terms

  • Alcoholism / drug therapy*
  • Alcoholism / physiopathology
  • Alcoholism / psychology
  • Animals
  • Clinical Trials as Topic / methods*
  • Clinical Trials as Topic / trends
  • Humans
  • Risk Factors
  • Sodium Oxybate / adverse effects
  • Sodium Oxybate / therapeutic use*
  • Substance-Related Disorders / etiology
  • Substance-Related Disorders / prevention & control
  • Substance-Related Disorders / psychology

Substances

  • Sodium Oxybate